Artificial intelligence can improve patients’ experience in decentralized clinical trials
The clinical trials industry is undergoing a rapid transition toward decentralization, accelerated by the need to continue running clinical trials during the COVID-19 pandemic. Research since then has continued to find that decentralization provides an opportunity to recruit larger, more diverse pools of patients. However, for these potential benefits to be fully realized, further innovation is necessary to compensate for the increased responsibility that decentralized clinical trials place on participants. The automation that artificial intelligence (AI) enables is particularly attractive for this reason, as it could fuel user interface improvements that would usher in the next generation of decentralized clinical trial applications.
Read more on the topic in Nature Medicine.